Chemomab Therapeutics’ Touts Positive Data From Experimental Drug For Chronic Liver Disease

All NewsMarch 27, 2025

Chemomab’s OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent